Ranbaxy launches authorized generic diabetes drug

Drug maker announces release of version of Takeda's Actos

PRINCETON, N.J. — Ranbaxy Labs has launched an authorized generic version of a diabetes drug made by Takeda Pharmaceutical, Ranbaxy said Friday.

Ranbaxy announced the launch, through subsidiary Ranbaxy Pharmaceuticals and under an agreement with Takeda, of pioglitazone hydrochloride tablets, an authorized generic version of Takeda's Actos. An authorized generic is a branded drug marketed at a reduced price under its generic name, typically by a third-party company operating under contract with the original branded drug's manufacturer.

Actos, used to treat Type 2 diabetes, had sales of $2.7 billion during the 12-month period ended in June, according to IMS Health.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Recommended stories

Login or Register to post a comment.